Serina CSO exercises options, sells 6,500 shares

Serina Therapeutics Chief Scientific Officer exercises options and sells shares.

Rhea-AI Filing Summary

Serina Therapeutics Chief Scientific Officer exercises options and sells shares. On January 28, 2026, Randall Moreadith exercised a stock option for 6,500 shares of common stock at an exercise price of $0.06 per share.

That same day he sold 6,500 common shares at a weighted average price of $3.567 per share, with individual sale prices ranging from $3.55 to $3.59, leaving 0 common shares directly owned after the sale and 319,686 stock options beneficially owned.

Insider Trade Summary

Exercise and Sale: 6,500 shares ($23K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Moreadith Randall

Role Chief Scientific Officer

Sold 6,500 shs ($23K)

Approx. gross sale proceeds $23K

Approx. exercise cost $390.00

Approx. pre-tax spread $23K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	6,500	$0.00	$0.00
Exercise	Common Stock	6,500	$0.06	$390.00
Sale	Common Stock	6,500	$3.567	$23K

Holdings After Transaction: Stock Option (right to buy) — 319,686 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
2. F2. The stock options are fully vested.

FAQ

What insider transaction did Serina Therapeutics (SER) report for January 28, 2026?

Serina Therapeutics reported that Chief Scientific Officer Randall Moreadith exercised options for 6,500 common shares at $0.06 per share, then sold all 6,500 shares at a weighted average price of $3.567 per share on January 28, 2026.

How many Serina Therapeutics (SER) shares did the CSO sell and at what price?

Randall Moreadith sold 6,500 shares of Serina Therapeutics common stock at a weighted average price of $3.567 per share, with individual trades executed between $3.55 and $3.59 per share, according to the Form 4 filing.

What stock options did the Serina Therapeutics (SER) CSO exercise in this Form 4?

The Chief Scientific Officer exercised a stock option for 6,500 shares of Serina Therapeutics common stock at an exercise price of $0.06 per share. The filing notes these stock options are fully vested and remain part of a larger option position.

How many Serina Therapeutics (SER) shares and options does the CSO hold after the transaction?

After the reported transactions, Randall Moreadith directly owned 0 shares of Serina Therapeutics common stock and held 319,686 stock options. These figures reflect the exercise of 6,500 options and the sale of the resulting 6,500 common shares on January 28, 2026.

Who is the insider involved in this Serina Therapeutics (SER) Form 4 filing?

The insider is Randall Moreadith, Chief Scientific Officer of Serina Therapeutics. The Form 4 indicates he is an officer but not a director or 10% owner, and it reports his option exercise and same-day sale of the resulting common shares.

What does the weighted average sale price mean in the Serina Therapeutics (SER) Form 4?

The weighted average sale price of $3.567 per share reflects multiple trades between $3.55 and $3.59. The filing states Moreadith will provide detailed trade breakdowns upon request to Serina Therapeutics, its security holders, or SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/29/2026 - 12:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moreadith Randall

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE AL 35806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		M		6,500	A	$0.06	6,500	D
Common Stock	01/28/2026		S		6,500	D	$3.567(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.06	01/28/2026		M			6,500	(2)	05/06/2031	Common Stock	6,500	$0	319,686	D

Explanation of Responses:

1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

2. The stock options are fully vested.

Remarks:

	/s/ Randall Moreadith	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.